From WikiMD's Food, Medicine & Wellness Encyclopedia

18-Methoxycoronaridine (18-MC) is a derivative of ibogaine invented in 1996 by the team around the pharmacologist Stanley D. Glick from the Albany Medical College and the chemist Martin E. Kuehne from the University of Vermont. In animal studies it has proved to be effective in suppressing self-administration of morphine, nicotine, alcohol, and methamphetamine.

History[edit | edit source]

18-MC was first synthesized in the lab of Martin Kuehne in 1996. The goal was to create a compound that could treat addiction without the hallucinogenic effects of ibogaine. The team of Stanley Glick and Martin Kuehne achieved this by altering the ibogaine molecule, removing a methoxy group and adding one at a different point, which resulted in 18-MC.

Pharmacology[edit | edit source]

18-MC is a sigma receptor antagonist and nicotinic acetylcholine receptor antagonist. It is believed to act primarily on the α3β4 nicotinic acetylcholine receptors in the brain, which are believed to be involved in addiction to several different substances.

Clinical trials[edit | edit source]

In 2018, the company MindMed started a phase 1 clinical trial for 18-MC as a potential treatment for opioid addiction. The trial is expected to be completed in 2021.

See also[edit | edit source]

References[edit | edit source]

External links[edit | edit source]

18-MC Resources
Doctor showing form.jpg

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD